IL-1β is often released in response to various PAMPs and DAMPs, inflammasomes activated through various infections and activation of the P2X7 receptor, whose dysregulation has been linked to increased poor outcomes in cancerous growths [70]. The gene discussed is P2RX7; the disease is infection.